Astellas Pharma (OTCMKTS:ALPMY) is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide). In oncology, Astellas has also partnered on Padcev (enfortumab vedotin) for urothelial cancer. The company maintains a robust pipeline spanning small molecules, biologics and gene-based therapies, targeting both rare and common diseases with high unmet medical need.
Formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has grown its presence across more than 50 countries and regions, including North America, Europe, Asia Pacific and emerging markets. The organization operates research centers in the United States, Japan and Europe, alongside manufacturing sites and commercial operations worldwide.
Under the leadership of President and Chief Executive Officer Naoki Okamura, Astellas continues to pursue strategic alliances and acquisitions to expand its therapeutic reach. The company places strong emphasis on sustainability and corporate social responsibility, aiming to improve global health through scientifically driven innovation and patient-centered care.
